Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Binimetinib + PLX8394 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Binimetinib | Mektovi | ARRY-162|ARRY-438162|MEK162 | MEK inhibitor (Pan) 26 MEK1 Inhibitor 26 MEK2 Inhibitor 24 | Mektovi (binimetinib) inhibits MEK1 and MEK2 resulting in inhibition of growth factor-mediated signaling and decreased tumor cell proliferation (PMID: 23587417). Mektovi (binimetinib) in combination with Braftovi (encorafenib) is FDA approved for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (FDA.gov). |
PLX8394 | PLX 8394|PLX-8394|FORE8394|FORE-8394|FORE 8394|Plixorafenib | BRAF Inhibitor 25 CRAF Inhibitor 12 | PLX8394 is a RAF inhibitor that inhibits wild-type and mutant BRAF, as well as CRAF, and does not paradoxically activate MAPK signaling, potentially resulting in decreased proliferation of BRAF-mutant tumor cells (PMID: 26466569, PMID: 24283590, PMID: 28659148, PMID: 30559419). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colorectal cancer | predicted - sensitive | Binimetinib + PLX8394 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Mektovi (binimetinib) and PLX8394 inhibited viability of colorectal cancer cells harboring BRAF V600E in culture (Cancer Res (2024) 84 (6_Supplement): 4609). | detail... |
BRAF V600E | melanoma | predicted - sensitive | Binimetinib + PLX8394 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Mektovi (binimetinib) and PLX8394 inhibited viability of melanoma cells harboring BRAF V600E in culture (Cancer Res (2024) 84 (6_Supplement): 4609). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|